Ironwood Pharmaceuticals Inc
$ 3.79
1.07%
24 Feb - close price
- Market Cap 610,045,000 USD
- Current Price $ 3.79
- High / Low $ 3.79 / 3.60
- Stock P/E 20.83
- Book Value -1.62
- EPS 0.18
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.23 %
- ROE -5.75 %
- 52 Week High 5.78
- 52 Week Low 0.53
About
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$4.85
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-10 | 2025-08-11 | 2025-05-07 | 2025-02-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-09 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 0 | 0.24 | 0.14 | -0.14 | 0.02 | 0.02 | -0.0054 | -0.02 | -0.01 | 0.09 | 0.31 | 0.25 |
| Estimated EPS | 0.0168 | 0.11 | 0.03 | 0.2 | 0.0775 | 0.08 | 0.15 | 0.19 | 0.21 | 0.16 | 0.25 | 0.24 |
| Surprise | -0.0168 | 0.13 | 0.11 | -0.34 | -0.0575 | -0.06 | -0.1554 | -0.21 | -0.22 | -0.07 | 0.06 | 0.01 |
| Surprise Percentage | -100% | 118.1818% | 366.6667% | -170% | -74.1935% | -75% | -103.6% | -110.5263% | -104.7619% | -43.75% | 24% | 4.1667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRWD
2026-02-10 04:28:06
Ironwood Pharmaceuticals (NASDAQ:IRWD) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $3.68. Several brokerages, including Wells Fargo and Citizens JMP, recently upgraded their ratings and raised price targets. The company beat Q3 earnings and revenue expectations, and institutional buying has significantly increased, indicating strong investor confidence despite recent stock fluctuations.
2026-02-03 16:27:45
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Ironwood Pharmaceuticals (NASDAQ:IRWD) by 76.3% in the third quarter of 2025, selling 401,900 shares and retaining 124,875 shares valued at $164,000. Despite this, analyst sentiment remains largely positive, with several firms upgrading IRWD to "strong-buy" or "outperform," resulting in a consensus "Moderate Buy" rating and an average target price of $3.68. Ironwood Pharmaceuticals recently reported stronger-than-expected earnings for the quarter, with an EPS of $0.24 against a $0.09 consensus and revenue of $122.06 million, surpassing expectations of $74.22 million.
2026-01-30 12:32:09
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) is presented as a strong candidate fitting Mark Minervini's "Trend Template" and "High Growth Momentum" criteria. The stock demonstrates technical strength with its price above key moving averages and high relative strength, coupled with robust fundamental growth including 1100% EPS growth and positive analyst revisions. Despite a high overall technical rating, the article notes a lower setup quality for immediate purchase, suggesting waiting for price stability.
2026-01-21 17:57:44
Ironwood Pharmaceuticals (NASDAQ:IRWD) saw its shares jump 8.4% on Wednesday following a strong earnings report that beat analyst expectations for both EPS and revenue. The company also received several analyst upgrades and higher price targets, leading to a "Moderate Buy" consensus rating. Despite light trading volume, the positive sentiment reflects investor confidence in the company's recent performance and future outlook.
2026-01-18 19:01:56
This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 94.00%, raising it to $4.95. No other details are provided in the current content.
2026-01-16 04:57:34
Ironwood Pharmaceuticals (IRWD) announced its financial guidance for full-year 2026, expecting LINZESS U.S. net sales of $1.125 to $1.175 billion and adjusted EBITDA greater than $300 million, despite lowering the LINZESS list price. The company maintains its 2025 financial guidance and plans to initiate a confirmatory Phase 3 trial for apraglutide in early 2026 for short bowel syndrome. The anticipated increase in net sales for LINZESS in 2026 is attributed to the elimination of the inflationary component of statutory rebates following the price decrease.
